Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Crenolanib - AROG Pharmaceuticals

Drug Profile

Crenolanib - AROG Pharmaceuticals

Alternative Names: ARO-002; ARO-002-26; CP-868,596; CP-868,596-26; Crenolanib besilate; Crenolanib besylate; IND 112201

Latest Information Update: 08 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer AROG Pharmaceuticals; University of Ulm
  • Class Antineoplastics; Benzimidazoles; Piperidines; Quinolines; Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Platelet derived growth factor alpha receptor antagonists; Platelet-derived growth factor beta receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Glioma; Soft tissue sarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia; Gastrointestinal stromal tumours
  • Phase II Glioblastoma; Non-small cell lung cancer
  • Phase I Gastric cancer; Oesophageal cancer
  • Preclinical Systemic mastocytosis
  • Research Soft tissue sarcoma
  • No development reported Glioma

Most Recent Events

  • 01 Apr 2019 Arog Pharmaceuticals completes a phase II trial for Acute myeloid leukaemia (Second-line therapy or greater) in USA (PO) (NCT01657682)
  • 08 Jan 2019 AROG Pharmaceuticals withdraws a phase II trial prior to enrolment for Acute myeloid leukaemia (Combination therapy, Second-line therapy or greater, In infants, In children, In adolescents, In adults) (PO) (NCT03324243)
  • 01 Dec 2018 Updated efficacy data from a phase II trial in Acute myeloid leukaemia presented at the 60th Annual Meeting and Exposition of the American Society of Hematology (ASH-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top